Kornimate/medical-research-clean huggingface dataset:
neuroplasticity:melatonin and transcranial current stimulation in healthy subjects.

Conditions: Analgesia Disorder; Pain

Summary: pain exerts a tremendous cost in healthy care, rehabilitation and lost productivity. it is is associated with a wide range of diseases and their social consequences is a public health problem. with the progress of neuroscience and studies on the plasticity of the central nervous system, it has been provided a better understanding of the neurobiological mechanisms of pain. the neurohormone melatonin stands by having systemic and diverse mechanisms of action, both in physiological and pathological situations, with modulating effects on the process of nociceptive signaling and neurochemical mechanisms such as serotonergic, opioidergic and gabaergic, exerting anti-inflammatory action, analgesic activity among others. the advent of neuromodulation techniques such as transcranial direct current stimulation (tdcs), which promote changes in neuronal activity and signaling to be effective in conditions of chronic pain by attenuating changes in cortical excitability. there is clinical evidence of the analgesic effect of melatonin and tdcs alone. thus, considering the potential for each isolated intervention and the lack of knowledge of their combined effect, the authors propose the present study to investigate the effect of this combination on the heat-pain detection threshold and the neuroplasticity in the healthy subjects.

the methods are according to the consort guidelines. heat pain threshold and tolerance : quantitative sensory testing (qst) will be used on a computer peltier-based device thermode. conditioned pain modulation (cpm)-task: immerssing the non-dominant hand cold water for 1 minute. serum brain derived neurotrophic factor (bdnf). transcranial magnetic stimulation (tms) assessment: motor threshold, motor evoked potential, short intracortical inhibition and intracortical facilitation. statistical analyses: descriptive statistics, linear and multiple regression analysis, performed with spss version18.0.

Eligibility criteria:
inclusion criteria: * male 18-40 years old * healthy * without medication * sign the informed consent exclusion criteria: * patients who did not understand the portuguese * acute or chronic pain conditions * medical or psychiatric disorders * history of alcohol or substance abuse * neurological disorder * use of medications affect in the central nervous system * traumatic brain injury * neurosurgery * metallic implant in the brain

Keywords: melatonin transcranial direct current stimulation neuroplasticity analgesia pain
postoperative pain in shoulder surgery

Conditions: Pain, Postoperative

Summary: after the approval of the ethics committee, the files of the patients who underwent arthroscopic shoulder surgery between 01.01.2019 and 01.03.2020 were evaluated retrospectively. data were recorded including age, gender, duration of anesthesia, duration of surgery, postoperative analgesia consumption, complications such as respiratory distress due to hemidiaphragmatic paralysis and complications such as hematoma and nerve damage due to block intervention.

patients who underwent arthroscopic shoulder surgery and underwent usg-guided interscalene block and concomitant suprascapular block were included in the study. we tried to determine whether there is a difference between different dose regimens in order to determine the effective analgesic dose and minimize the side effects of dose-dependent interscalene block applications.

Eligibility criteria:
inclusion criteria: arthroscopic shoulder surgery full data form exclusion criteria: chronic obstructive lung disease chronic opoid consumption missing data from the postoperative pain form
gt201 injection for the treatment of advanced solid tumors

Conditions: Solid Tumor, Adult

Summary: expected to complete 7 to 18 evaluable subjects (patients with advanced solid tumors)，3 dose groups.a modified "3+3" dose-escalation design is utilized,this includes both accelerated dose escalation and traditional "3+3" dose escalation.the first dose group is accelerated titration,the first dose group is an accelerated titration of 1 to 6 evaluable subjects;the second and third dose groups are based on the traditional "3+3" dose-escalation principle,the second and third dose groups are based on the traditional "3+3" dose-escalation principle, with 3 to 6 evaluable subjects enrolled respectively.


Eligibility criteria:
inclusion criteria: * 1. the patients (or legally authorized representative) patients (or legally authorized representative) must have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an informed consent form (icf) approved by an institutional review board/independent ethics committee (irb/iec), must have the ability to understand the requirements of the study; * 2.must have a confirmed diagnosis of malignancy of their receptive histologies or cytologies; * 3.at least one resectable lesion (preferably superficial metastatic lymph nodes) that has not been treated with radiation and has not received other local therapies. the separated tissues ≥1.0cm\^3 (either of single lesion origin or multiple lesions combined) for the preparation of autologous tumor-infiltrating lymphocytes. minimally invasive treatment where possible. exclusion criteria: * 1.the patient who has any active autoimmune disease, history of autoimmune disease, need for systemic steroid hormones or a condition requiring immunosuppressive drug therapy (\>10 mg/day of prednisone or equivalent hormone); * 2. arterial/venous thrombotic events within 3 months prior to enrollment, such as: cerebrovascular accident, deep vein thrombosis and pulmonary embolism occurring; * 3. patients who have refractory or intractable epilepsy, poorly controlled hydrothorax, hydrops abdominis, pericardial effusion or il-2 contraindications; * 4. participate in other clinical trials within 4 weeks prior to the first dose of this study, or planning to participate in this study and other clinical trials at the same; * 5. patients who have received allogeneic bone marrow transplantation or an organ allograft; * 6.patients who have a history of hypersensitivity to any component or excipient of study drugs: autologous tumor infiltrating lymphocytes, cyclophosphamide, fludarabine, il-2, dimethyl sulfoxide (dmso), human serum albumin (hsa), dextran-40 and antibiotics (beta lactam antibiotics, gentamicin).
reduction in clinical variance using targeted design changes in computerized provider order entry order (cpoe) sets

Conditions: Asthma Exacerbation

Summary: selective redesign of order sets using different ways to frame the order and physician decision-making in a computerized provider order entry system could increase adherence to evidence-based care and reduce population-specific variance.

variance in ordering of care can be characterized as the lack of uniform use of specific treatments by clinicians for a given medical condition. unwarranted variance in healthcare has been associated with prolonged length of stay, diminished health and increased cost. practice variation in the management of asthma can be significant and few investigators have evaluated strategies to reduce this variation. we hypothesized that selective redesign of order sets using different ways to frame the order and physician decision-making in a computerized provider order entry system could increase adherence to evidence-based care and reduce population-specific variance.

Eligibility criteria:
inclusion criteria: * all patients admitted using an acute asthma exacerbation order set. exclusion criteria: * patients who did not have either an admission or discharge diagnosis of asthma exacerbation. * in addition, patients admitted to the intensive care unit directly or transferred to the intensive care unit within 24-hours were excluded from analysis. * finally, patients were excluded from analysis if asthma was not the presenting problem.

Keywords: asthma children cpoe decision support framing heuristic order sets
non-inferiority and safety study of eutcv compared to typbar-tcv in healthy 6 months-45 years aged participants

Conditions: Typhoid Fever

Summary: this is an observer-blinded, comparative, single dose, clinical phase ii/iii study to assess the immunogenicity and safety of eutcv compared to typhoid conjugate vaccine in healthy filipino participants aged 6 months to 45 years.


Eligibility criteria:
inclusion criteria: 1. healthy participants ≥6 months and ≤45 years of age at enrolment 2. participants/parents/legally authorized representative(lar) willing to give written informed consent/assent to participate in the trial 3. participants/parents/lar willing to follow the study procedures of the study and available for the entire duration of the study 4. participants who are healthy as determined by medical history, with no clinically significant abnormalities in clinical examination and laboratory tests 5. female participants must have a negative serum (at screening) and negative urinary (at day 1) pregnancy test and agree to use 2 methods of contraception from dosing until 90 days after vaccination. exclusion criteria: 1. participants/parents/lar unwilling to give his/her consent/assent to participate in the trial 2. participants concomitantly enrolled or scheduled to be enrolled in another trial 3. children and infants with a congenital abnormality 4. known history of immune function disorders including immunodeficiency disease, or chronic use of systemic steroids, cytotoxic or other immunosuppressive drugs 5. pregnant, lactating women or women of childbearing age not using a reliable method of contraception 6. history of uncontrolled coagulopathy or blood disorders 7. any abnormality or chronic disease which in the opinion of the investigator might be detrimental for the safety of the participant and interfere with the assessment of the trial objectives 8. history of alcohol or substance abuse
comparison of subjective experiences between patients receiving clear aligners or fixed appliances

Conditions: Pain; Anxiety; Quality of Life

Summary: this study aimed to compare experiences between adult patients receiving clear aligners and fixed appliances during the initial stage of orthodontic treatments.

patients receiving either clear aligner treatments were enrolled in this study. during the same time period, patients receiving fixed orthodontic treatments well-matched with clear-aligner patients by similar ages (difference \< 3 years), same gender and similar levels of severity of malocclusion \[similar index of complexity outcome and need (icon) level\] were enrolled.the two groups were well-matched with ages, gender and levels of malocclusion severity. pain perception, anxiety and quality of life were assessed through visual analogue scale (vas), state-trait anxiety inventory (stai) and oral health impact profile-14 (ohip-14), respectively.

Eligibility criteria:
inclusion criteria: * must be 18 years of age or older; * must be in good general health; * upper and lower arches were both involved in two groups; * the fixed appliances group must be treated with wires and brackets only with the initial arch wire of 0.012 niti ; * must be willing to sign and give written informed consent in accordance with institutional and federal guidelines. exclusion criteria: * once been undergoing with orthodontic treatment; * experienced tooth ache recently; * been diagnosed with contagious and/or systematical diseases; * have taken any kind of painkillers three days before the initial treatment; * when trait anxiety inventory (t-ai) shows a score believed to define a psychological state of over anxiety (male over 53 points and female over 55 points).
sars-cov-2 antibodies and virus neutralisation in a cohort vaccinted against covid-19

Conditions: Vaccine Reaction

Summary: analysis of sars-cov-2 antibodies and serum virus neutralisation in vaccinated heath care personnel. analysis of virus neutralisation as a function of age, gender, and history of covid-19 infection.

this study is an observational study with subsequent use of coded biological material. sera of universitiy hospital of zurich (usz) personnel vaccinated with bnt162b2 (biontech/pfizer) was analyzed for sars-cov-2 specific antibodies and virus neutralization. serum was analysed for virus-specific igg and iga using elisa kits from euroimmun (kriens, switzerland) according to the manufacturer's instruction. igg was determined with the quantitative anti-sars-cov-2 quantivac kit and iga was determined with the semi-quantitative anti-sars-cov-2 kit the kits determine antibodies against the spike-1 protein. the sera were not diluted and not heat-inactivated prior to testing. the developed 96-well plates were analysed by reading absorbance at 450 nm using an elx808 elisa reader from biotek instr. inc. in addition, a sars-cov-2 neutralization assay was developed at the department. in this tissue culture infection dose (tcid) assay, vero cells were infected with live sars-cov-2, and sera were added at various dilutions to test the potential to neutralize viral infection. the assay was conducted in a biosafety level 3 lab. briefly, vero-e6 cells were grown overnight to ca. 80-90% adherence in flat-bottom 96-well cell culture plates. the sars-cov-2 was then mixed in round-bottom 96 well titre plates with 2-fold serial dilutions of serum and incubated. the virus-serum mixture was then added to the vero-e6 cell, and the cultures were incubated again. after three days, the cultures were fixed by addition of paraformaldehyde and stained with crystal violet for visualisation of cytotoxicity. the highest serum dilution preventing infections of the cells was defined as the neutralization titre.

Eligibility criteria:
inclusion criteria: * employed at the usz department of dermatology * vaccinated against covid-19 at usz * male and female persons of any age * serum samples collected in 2020 or until june 11th 2021 * the subject was informed and gave his/her consent to the research project (non-coded samples and data) and to publish data obtained from analysis of own biological samples exclusion criteria: * known clinical relevant disease, e.g. immune suppressed by drugs or disease * documented objection of subsequent use and publication of biological samples and personal health data
clinical value of next generation sequencing in chinese childhood solid tumors

Conditions: Pediatric, Solid Tumors, NGS

Summary: samples of 200 patients with pediatric malignant solid tumors will prospectively be collected. selected samples are sufficient for next generation sequencing(ngs) and available for follow-up information. multi-omics techniques such as dna and rna panel will be used to study driver genes for the development of malignant solid tumors in children, and to explore the pathogenic mechanism. the aim of this study is to explore new biomarkers for the diagnosis and treatment for childhood malignant solid tumors.

dna and rna extracted from tumor tissues and leukocytes will be analyzed by onco panscan/whole exon sequencing(genetronhealth), and comprehensive gene mutation information such as single nucleotide variation, insertion deletion mutation, gene copy number variants and structure variants will be obtained. through in-depth mining of genomic data generated by clinical tumor tissue detection, the differences among different subtypes of pediatric solid tumors in tcga data will be compared with previous studies. combined with clinical pathological and molecular subtyping results, auxiliary diagnosis was performed. analyzing therapeutic targets and identifying pathogenic cancer-predisposing variants may provide molecular reference for children's malignant solid tumors.

Eligibility criteria:
inclusion criteria: 1. patients are diagnosed by histology and pathology as pediatric malignant solid tumors (including soft tissue sarcoma, osteosarcoma, pediatric glioma, neuroblastoma, nephroblastoma, retinoblastoma, hepatoblastoma, atypical teratoid/rhabdomymoma, embryonal tumor, etc.); 2. age: \< 18 years old; 3. eastern cooperative oncology group (ecog) ps score: 0-2, estimated survival \>6 months; 4. complete clinical laboratory examination and pathological examination information of patients; 5. patients can be evaluated on time, and samples can be obtained throughout the whole test process; 6. informed consent signed by the patient or his/her legal representative shall be obtained after the patient is informed of the project; exclusion criteria: 1. as determined by the investigator, the patient had other major diseases that might affect follow-up and short-term survival; 2. any social/psychological problems that the researcher determines are not suitable for the study;
do we need computer assistance to improve the survival of primary total knee arthroplasty. a minimum ten years follow-up

Conditions: Osteoarthritis

Summary: the investigators asked: (1) do computer-assisted total knee arthroplasty (tkas) provide better alignment and clinical function? (2) do computer-assisted tkas provide better survivorship of implants and less complication? and (3) do correction of the mechanical axis of the lower limb to within 3° of neutral is a prognostic marker for late revision surgery due to aseptic loosening?

computer-assisted total knee arthroplasty (tka) is reported to improve the overall accuracy of positioning of the femoral and tibia components. however, an acceptable target for alignment remains a matter for debate. a mechanical axis within 3° of neutral axis has been used as the primary outcome measure in many clinical trials comparing computer-assisted- and conventional tka. however, the evidence supporting this arbitrary value is unreliable because previous reports are limited by their small sample size, inadequate radiographs, short follow-up and lack of clarity when defining a margin of accuracy.

Eligibility criteria:
inclusion criteria: * end stage osteoarthritis of the knee joint who require total knee arthroplasty with bilateral lesions. exclusion criteria: * inflammatory disease * patient with other lower extremity disease which may affect functional outcome * neurologic disease effecting patients lower extremity * revision surgery * patient not medically cleared for bilateral surgery

Keywords: computer assistance total knee arthroplasty conventional
long term outcome of easophageal atresia : transmics profiles in adolescence

Conditions: Esophageal Atresia

Summary: oesophageal atresia (oaea), a malformation of the oesophagus present from birth, is characterized by the interruption of the continuity of the oesophagus, which then ends in a cul-de-sac. (source: fimatho) an operation is then required to restore continuity to the esophagus. although this operation enables the vast majority of children to survive the neonatal period, health problems such as gastro-oesophageal reflux, eating difficulties, respiratory problems and growth problems persist throughout life. the aim of the project is to create a prospective cohort of adolescents aged 13/14, nested in the national ao registry. of adolescents born with esophageal atresia, including a biobank of esophageal mucosa and plasma blood samples. once the clinical and omic data have been collected, the data will be transferred to the france cohortes information system for analysis, in order to assess the long-term outcome of this rare disease and establish multi-omic profiles. once the clinical data have been collected and the omics data (derived from analysis of the biobank's biological samples) have been generated, they will be analyzed by the project partners to assess the long-term outcome of oa and establish multiomic profiles. the raw data will be available on the france cohorte platform.


Eligibility criteria:
inclusion criteria: * for the oesophageal atresia group : * born with oesophageal atresia (ea) in france or in french overseas departments and territories * anastomosis performed * included into the renato registry * aged 13 or 14 during the recruitment period * patient willing to comply with all study procedures and duration * patient will social security for the blood sub-study : * upper gi endoscopy performed as part of care between 13 and 14 years of age with esophageal mucosal biopsy sampling * patient having given written consent to participate in the study for the control arm: * upper gi endoscopy performed as part of care between 10 and 14 years of age with oesophageal mucosal biopsy sampling * upper gi endoscopy performed as part of care for chronic or acute digestive signs to rule out organic etiology (peptic esophagitis, gastric esophagitis, eosinophilic esophagitis or ulcer) * normal endoscopy and histology * no chronic progressive disease exclusion criteria: * for the oesophagal atresia arm : * concurrent participation in an interventional trial and in the 3 months prior to inclusion * parents refusing to participate in the study for the control arm : * histologically non-normal esophageal biopsy * parents refusing to participate in the study * child with known organic pathology
study to evaluate the safety and efficacy of oral vadadustat in pediatric participants with anemia of chronic kidney disease

Conditions: Anemia of Chronic Kidney Disease

Summary: this study will assess the safety and efficacy of once daily dosing of vadadustat for the treatment of pediatric participants with anemia of chronic kidney disease (ckd) after conversion from an erythropoiesis stimulating agent (esa).


Eligibility criteria:
inclusion criteria: * diagnosis of anemia of chronic kidney disease (ckd) * diagnosis of non-dialysis-dependent (ndd) ckd with an estimated glomerular filtration rate of greater than (\>) 10 and less than (\<) 60 milliliters/minute/1.73 meters\^2 (ml/min/1.73 m\^2) or diagnosis of dialysis dependent (dd) ckd * mean hemoglobin (hb) between 9.0 and 12.0 grams/deciliters (g/dl) (inclusive) * transferrin saturation ≥ 20% exclusion criteria: * anemia due to a cause other than ckd * active bleeding or recent clinically significant blood loss * history of sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia * red blood cells transfusion within 4 weeks * serum albumin level less than 2.5 g/dl * uncontrolled hypertension * active malignancy or treatment for malignancy within the past 2 years prior to screening * evidence of iron overload or diagnosis of hemochromatosis * known hypersensitivity to vadadustat or any excipients in vadadustat tablet

Keywords: anemia kidney disease vadadustat pediatric population children chronic kidney disease erythropoiesis stimulating agent dialysis hypoxia-inducible factor (hif) prolyl hydroxylase inhibitor